One of the central features of insulin's action on the liver is its ability to antagonize the actions of glucagon. Glucagon switches on glycogenolysis and gluconeogenesis in the liver by raising intracellular cyclic AMP concentrations through stimulating the activity of adenylate cyclase. Insulin would appear to achieve its antagonistic effect by causing a decrease in the intracellular concentrations of cyclic AMP.
Although insulin is known to exert actions on target cells which are independent of alterations in intracellular cyclic AMP concentrations, we believe that adenylate cyclase and cyclic AMP phosphodiesterases can be employed as useful probes to identify aspects of insulin's molecular mechanism of action.
Intracellular concentrations of cyclic AMP are determined by the action of adenylate cyclase, a plasmamembrane enzyme, and a family of cyclic AMP phosphodiesterases, which occur as both soluble and particulate forms (see Houslay et af., 1983) . If hepatocytes are incubated with insulin then we (Heyworth et al., 19836) have been able to demonstrate that the activity of two distinct cyclic AMP phosphodiesterases is markedly increased. These are a plasma-membrane enzyme and the so-called 'dense-vesicle' enzyme, which is found associated with an intracellular membrane fraction.
The plasma-membrane enzyme has been studied by us (Marchmont & Houslay, 1980a; Marchmont et al., 1981) in some detail. It is a monomeric enzyme which expresses high affinity for cyclic AMP, but not cyclic GMP, yet exhibits kinetics indicative of apparent negative co-operativity. This is believed to be due to it obeying an unusual type of kinetic mechanism (mnemonical), which enhances the degree of activation achieved at physiological substrate concentrations. This enzyme is found loosely associated with the plasma membrane and can be displaced by increasing the ionic strength or the addition of chelating agents such as EGTA/EDTA. It can thus be considered a peripheral membrane protein. Nevertheless, it is found specifically associated with the plasma membrane where it binds to a single species of integral membrane protein (Marchmont & Houslay, 198 1) . The plasma-membrane phosphodiesterase, is presumably anchored to this location within the cell as it is not found associated with any other membrane fraction (Cercek & Houslay, 1982; Cercek et al., 1983) . From binding studies and from our purification procedures it is possible to estimate that about 26000 copies of this phosphodiesterase are associated with the plasma membrane of each hepatocyte. This is of a similar magnitude to the number of insulin receptors in these cells.
How is the plasma membrane phosphodiesterase activated by insulin? It is possible to achieve activation of this enzyme, by insulin, in a broken membrane fraction (Marchmont & Houslay, 19806) . This, however, involves the incubation of purified plasma membranes with not only insulin but also MgATP and cyclic AMP for about 3-5min at 30°C. After such an incubation the phosphodiesterase is activated almost 2-fold. The process is concentration dependent upon insulin, cyclic AMP and MgATP, with half-maximal effects occurring at 0.1 nM, 1.6pM and 25 p~ respectively. Considering that the intracellular concentrations of cyclic AMP are of this order of magnitude and MgATP concentrations are well in excess of this, then we can expect that physiological concentrations of insulin would trigger the activation of this enzyme in intact hepatocytes. This we have indeed observed (Heyworth et al., 19836) .
The requirement for both MgATP and cyclic AMP to elicit activation of the phosphodiesterase by insulin suggested that a phosphorylation process might be involved. Indeed if activation was performed using [p3*P]-ATP then we were able to purify a phosphorylated form of the enzyme (Marchmont & Houslay, 1981) . It contained approximately 1 mol of alkali-labile phosphate per mol of enzyme. This could be removed by the action of either alkaline phosphatase or the endogenous phosphatase activity of rat liver cytosol. Such treatment caused the activity of the enzyme to resume that exhibited by the native enzyme. Furthermore, if plasma-membrane fractions containing the enzyme were obtained from hepatocytes treated with insulin, then alkaline phosphatase treatment also caused their phosphodiesterase activity to resume that observed in the basal state (Heyworth et al., 19836) . This suggests that both in hepatocytes and in broken plasmamembrane fractions, insulin exerts its stimulatory effect on 607th MEETING, LONDON this enzyme by triggering its phosphorylation. This processed is dependent upon cyclic AMP and can be blocked using an inhibitor of cyclic AMP-dependent protein kinase. It would appear then, that activation of the plasmamembrane phosphodiesterase is caused by an endogenous membrane-bound cyclic AMP-dependent protein kinase. We think it unlikely that the protein kinase activity found recently to form part of the insulin receptor itself is responsible for phosphorylating the plasma-membrane enzyme. This is because the insulin-receptor kinase activity appears not to be stimulated by cyclic AMP. The insulinreceptor kinase activity is unusual as it appears to transfer phosphate groups to tyrosine residues on target proteins rather than to serine/threonine, as is most common for the action of protein kinases. Nevertheless, such studies have been performed on solubilized receptor preparations and there is evidence that the functioning of the solubilized enzyme may be very different from that expressed in membranes and in intact cells (Kasugaet a/., 1982; Haring et a/., 1982) . We cannot then completely discount an involvement of this receptor kinase in the regulation of the plasmamembrane phosphodiesterase.
Exposure of intact hepatocytes to insulin causes the activation of both the plasma membrane and 'dense-vesicle' cyclic AMP phosphodiesterases. However, unlike the 'dense-vesicle' enzyme, the plasma-membrane phosphodiesterase was not activated by glucagon. Indeed, it was most surprising to find that pretreatment of hepatocytes with glucagon actually prevented insulin from activating the plasma-membrane phosphodiesterase. In contrast, such a treatment of hepatocytes, with glucagon followed by insulin, elicited a synergistic activation of the 'densevesicle' enzyme (Heyworth et a/., 19836) .
This blockade of insulin's activation of the plasmamembrane cyclic AMP phosphodiesterase did not occur as a consequence of the increased intracellular cyclic AMP content as it was not mimicked by raising such levels using either dibutyryl cyclic AMP or cyclic AMP phosphodiesterase inhibitors. Indeed such agents actually augmented insulin's effect on the plasma-membrane cyclic AMP phosphodiesterase (Heyworth et al., 19836) . Presumably, they raised the intracellular cyclic AMP concentrations well above the K, for the kinase involved in mediating the activation. This blockade of insulin's action was thus dependent upon glucagon itself, which exerted half-maximal effects at around 0.1 nM-glucagon and required a pre-exposure of the cells to glucagon for about 5 min before addition of insulin.
Glucagon is well known to extert a potent stimulatory effect on adenylate cyclase in both intact hepatocytes and in broken plasma membranes. This receptor-specific event is mediated by a particular species of guanine nucleotide regulatory protein, called 'N,' (see Ross & Gilman, 1980; Houslay, 1983) . In contrast to this extremely rapid activation process, which occurs within seconds of exposure of intact hepatocytes to glucagon, there follows a much slower process which achieves its maximal effect after several minutes. This slower process actually leads to the inhibition ('uncoupling') of glucagon-stimulated adenylate cyclase activity . Indeed, there would appear to be a remarkable similarity between this action of glucagon in 'uncoupling' adenylate cyclase from stimulation by glucagon and the action of glucagon in blocking insulin's activation of the plasma-membrane phosphodiesterase (Heyworth et al., 19836) . In both instances the maximal effect of glucagon was exerted after about 5min; halfmaximal effects occurred around 0.1 nM-glucagon, which is over an order of magnitude lower than those which elicit activation of adenylate cyclase, and neither effect appeared to be mediated by cyclic AMP. We have presented evidence which is consistent with the notion that glucagon 'uncouples' adenylate cyclase activity from hormonal stimulation by an, as yet unknown, modification of the guanine nucleotide regulatory protein, N,. As might be predicted this leads to the heterologous 'uncoupling' of adenylate cyclase from stimulation by either glucagon or isoprenaline. We (Heyworth et a/., 1983a,6; Heyworth & Houslay, 1983a,b) have therefore suggested that a specific guanine nucleotide regulatory protein may be involved in mediating at least certain of the actions of insulin. Clearly, such a guanine nucleotide regulatory protein would be distinct from that (N,) which mediates the action of stimulatory hormones on adenylate cyclase, as glucagon does not activate the plasma-membrane phosphodiesterase. This putative guanine nucleotide regulatory protein involved in mediating certain of the actions of insulin ('N,,,' ) would, however, be inactivated by whatever process glucagon achieves its 'uncoupling' action on N,.
Is there any other evidence which might support this hypothesis? One observation that we have made is that cholera toxin treatment of hepatocytes actually leads to the activation of the plasma-membrane phosphodiesterase (Heyworth et al., 19836) . Now cholera toxin is known to act on cells by causing the ADP ribosylation of membrane proteins. The major target for its action is N,, which becomes activated, causing a dramatic increase in adenylate cyclase activity (Ross & Gilman, 1980) . We know that the plasma-membrane phosphodiesterase cannot be activated through N, or by simply increasing cyclic AMP concentrations, and so we presume that cholera toxin also acts upon the putative Nl,. Furthermore, after treatment of the hepatocytes with cholera toxin no further stimulatory effect of insulin on the plasma-membrane phosphodiesterase can be observed. This is consistent with both cholera toxin and insulin acting on the enzyme via a similar route, i.e. via Nl,. It also parallels the action of cholera toxin on adenylate cyclase where the activated enzyme now shows little stimulatory response to glucagon. There is also a strong analogy with the high-affinity cyclic G M P phosphodiesterase in rod outer segments. This is a peripheral enzyme that is activated by rhodopsin when exposed to light. In this instance the action of rhodopsin is mediated by a guanine nucleotide regulatory protein called transducin, which can also be ADP-ribosylated and activated by cholera toxin (Bitensky et a/., 1978) . Transducin has been purified and shown to be distinct from N,, even though they are both acted upon by cholera toxin.
Further evidence which supports the involvement of a distinct guanine nucleotide regulatory protein involved in mediating insulin's action on the plasma membrane phosphodiesterase comes from broken membrane studies (Heyworth et a/., 1983~) . Here, it can be shown that G T P and its non-hydrolysable analogues p[NHlppG and GTP-y-S also elicit activation of the enzyme. This effect is, like that of insulin, dependent upon cyclic AMP and MgATP. Interestingly, activation of the phosphodiesterase required concentrations of GTP which were higher than those needed using the non-hydrolysable analogues. Similar observations have been made for the activation of the cyclic GMP phosphodiesterase by transducin. It would also appear to be the case for the functioning of yet another guanine nucleotide regulatory protein, called 'Nl', which mediates the action of inhibitory hormones on adenylate cyclase. The converse of this is, however, observed for the activation of adenylate cyclase by guanine nucleotides via N,. Unlike all of these guanine nucleotide regulatory proteins that have been fully characterized so far, it would seem that the guanine nucleotide diphosphates as well as triphosphates will allow the putative 'Nl,,' to function. Comparing N,, on a purely functional basis it would appear to express certain similarities with and differences between the various guanine nucleotide regulatory proteins that have been fully characterized to date.
It has been a matter of some contention as to whether insulin can exert an inhibitory effect upon adenylate cyclase activity. However, based upon our observations on the plasma-membrane cyclic AMP phosphodiesterase, it is apparent that such effects should only be observed at relatively high, but nevertheless physiological, GTP concentrations. Under such conditions we (Heyworth & Houslay, 19836) have indeed observed an inhibition of adenylate cyclase activity using low, physiological concentrations of insulin. As with insulin's action on the plasmamembrane cyclic AMP phosphodiesterase, no inhibition can be observed in broken membranes obtained from glucagon-treated ('uncoupled') hepatocytes where the putative Nin has presumably been modified. Similarly, no effect of insulin on adenylate cyclase activity can be seen in membranes from hepatocytes treated with cholera toxin where, presumably, both N,, and Nin are fully activated. The major ADP-ribosylated band in hepatocyte plasma membranes is N, and this undoubtedly exerts a dominating stirnulatory influence on adenylate cyclase in membranes from cholera toxin-treated cells and in assays containing high glucagon concentrations (Heyworth & Houslay, 19836 ).
These observations on the effect of insulin on adenylate cyclase activity lend support then to our contention that a distinct guanine nucleotide regulatory protein is involved in mediating certain of insulin's actions.
More recently we have been able to show that three distinct treatments block both the ability of glucagon to 'uncouple' adenylate cyclase activity and prevent insulin's activation of the plasma membrane cyclic AMP phosphodiesterase. These are either the pretreatment or preexposure of hepatocytes to adenosine, Ca2 + 4onophore and islet activating protein (IAP) from pertussis toxin. We believe that this emphasizes the inter-relationships between glucagon's 'uncoupling' of adenylate cyclase and its ability to block insulin's activation of the plasma-membrane phosphodiesterase (Heyworth et al., 1983b ). Importantly, it shows that glucagon can modify certain of insulin's actions at the level of the plasma membrane independently of its ability to affect intracellular cyclic AMP concentrations.
Clearly the putative Nin cannot mediate all of the effects of insulin that are exerted upon the cell. This is demonstrated by the 'dense-vesicle' enzyme whose activity is synergistically increased by treatment of hepatocytes with both glucagon and insulin. We have provided evidence that this enzyme is activated by insulin through a route which is independent from that used to activate the plasma membrane phosphodiesterase. In this case activation appears to ensue as a result of the internalization and subsequent processing of the insulin receptor or insulin itself .
The concept that insulin might exert widespread effects on cellular functioning by controlling the activity of specific membrane-bound protein kinases has been suggested by a number of investigators (Denton et al., 1981; Houslay, 1981) . The attraction of such a hypothesis is that it would provide the necessary degree of amplification and the diversity required to account for insulin's cellular effects. We envisage here that the putative guanine nucleotide regulatory protein, Nin, may itself mediate insulin's actions on membrane-bound protein kinases and perhaps even modulate the functioning of the kinase activity which is associated with the receptor itself. Insulin has profound effects on the metabolism of fat cells. Most striking is the large increase in the rate of conversion of glucose into fatty acids which is observed within a minute or so of exposure of fat cells to insulin. This increase is brought about by the parallel activation of a number of steps in the pathway including glucose transport across the plasma membrane, pyruvate dehydrogenase (a mitochondrial enzyme) and acetyl-CoA carboxylase (a cytoplasmic enzyme). In addition, in cells in which the concentration of cyclic AMP is increased by adrenaline or other hormones, insulin may cause a marked decrease in lipolysis by lowering the activity of triglyceride lipase. Under these conditions
